Sort by
Items per page

Send to

Choose Destination

Best matches for prostate cancer and curcumin:

Curcumin-based anti-prostate cancer agents. Chen QH et al. Anticancer Agents Med Chem. (2015)

Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment. Jordan BC et al. Life Sci. (2016)

Liposomal curcumin and its application in cancer. Feng T et al. Int J Nanomedicine. (2017)

Search results

Items: 1 to 20 of 349


Phytochemicals as Modulators of Long Non-Coding RNAs and Inhibitors of Cancer-Related Carbonic Anhydrases.

Saghafi T, Taheri RA, Parkkila S, Emameh RZ.

Int J Mol Sci. 2019 Jun 15;20(12). pii: E2939. doi: 10.3390/ijms20122939. Review.


Co-Delivery of Natural Compounds with a Dual-Targeted Nanoparticle Delivery System for Improving Synergistic Therapy in an Orthotopic Tumor Model.

Chu PY, Tsai SC, Ko HY, Wu CC, Lin YH.

ACS Appl Mater Interfaces. 2019 Jul 10;11(27):23880-23892. doi: 10.1021/acsami.9b06155. Epub 2019 Jun 25.


The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis.

Yang Y, Liu L, Li M, Cheng X, Fang M, Zeng Q, Xu Y.

Biochim Biophys Acta Gene Regul Mech. 2019 May 30. pii: S1874-9399(19)30029-X. doi: 10.1016/j.bbagrm.2019.05.005. [Epub ahead of print]


The targeting of non‑coding RNAs by curcumin: Facts and hopes for cancer therapy (Review).

Liu Y, Sun H, Makabel B, Cui Q, Li J, Su C, Ashby CR Jr, Chen Z, Zhang J.

Oncol Rep. 2019 Jul;42(1):20-34. doi: 10.3892/or.2019.7148. Epub 2019 May 3.


Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells.

Zhu M, Zheng Z, Huang J, Ma X, Huang C, Wu R, Li X, Liang Z, Deng F, Wu J, Geng S, Xie C, Zhong C.

J Cell Biochem. 2019 May 1. doi: 10.1002/jcb.28828. [Epub ahead of print]


Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.

Khurana N, Sikka SC.

Int J Mol Sci. 2019 Apr 26;20(9). pii: E2066. doi: 10.3390/ijms20092066. Review.


Effective encapsulation of curcumin in nanoparticles enabled by hydrogen bonding using flash nanocomplexation.

Ke X, Tang H, Mao HQ.

Int J Pharm. 2019 Jun 10;564:273-280. doi: 10.1016/j.ijpharm.2019.04.053. Epub 2019 Apr 19.


Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition.

Bahrami A, Majeed M, Sahebkar A.

Cell Oncol (Dordr). 2019 Aug;42(4):405-421. doi: 10.1007/s13402-019-00442-2. Epub 2019 Apr 13. Review.


Curcumin: Total-Scale Analysis of the Scientific Literature.

Yeung AWK, Horbańczuk M, Tzvetkov NT, Mocan A, Carradori S, Maggi F, Marchewka J, Sut S, Dall'Acqua S, Gan RY, Tancheva LP, Polgar T, Berindan-Neagoe I, Pirgozliev V, Šmejkal K, Atanasov AG.

Molecules. 2019 Apr 9;24(7). pii: E1393. doi: 10.3390/molecules24071393.


Evaluation of biophysical as well as biochemical potential of curcumin and resveratrol during prostate cancer.

Guo W, Wu X, Li Y, Gao J, Wang F, Jin Y, Chong T, Malhotra A.

J Drug Target. 2019 Apr 4:1-21. doi: 10.1080/1061186X.2019.1601199. [Epub ahead of print]


Prostate Cancer Disparity, Chemoprevention, and Treatment by Specific Medicinal Plants.

Yedjou CG, Mbemi AT, Noubissi F, Tchounwou SS, Tsabang N, Payton M, Miele L, Tchounwou PB.

Nutrients. 2019 Feb 4;11(2). pii: E336. doi: 10.3390/nu11020336. Review.


Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.

Chou FJ, Chen Y, Chen D, Niu Y, Li G, Keng P, Yeh S, Chang C.

EBioMedicine. 2019 Feb;40:504-516. doi: 10.1016/j.ebiom.2018.12.050. Epub 2019 Jan 26.


SP1 and RARα regulate AGAP2 expression in cancer.

Doush Y, Surani AA, Navarro-Corcuera A, McArdle S, Billett EE, Montiel-Duarte C.

Sci Rep. 2019 Jan 23;9(1):390. doi: 10.1038/s41598-018-36888-x.


A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation.

Choi YH, Han DH, Kim SW, Kim MJ, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY.

Prostate. 2019 May;79(6):614-621. doi: 10.1002/pros.23766. Epub 2019 Jan 22.


Low-dose curcuminoid-loaded in dextran nanobubbles can prevent metastatic spreading in prostate cancer cells.

Bessone F, Argenziano M, Grillo G, Ferrara B, Pizzimenti S, Barrera G, Cravotto G, Guiot C, Stura I, Cavalli R, Dianzani C.

Nanotechnology. 2019 May 24;30(21):214004. doi: 10.1088/1361-6528/aaff96. Epub 2019 Jan 17.


Potent Anti-Cancer Properties of Phthalimide-Based Curcumin Derivatives on Prostate Tumor Cells.

Belluti S, Orteca G, Semeghini V, Rigillo G, Parenti F, Ferrari E, Imbriano C.

Int J Mol Sci. 2018 Dec 21;20(1). pii: E28. doi: 10.3390/ijms20010028.


A Self-degradable Curcumin Polymer with Anti-cancer Activity.

O'Connor NA, Einbond LS, Redenti S, Sauane M, Jitianu A.

J Appl Polym Sci. 2018 Dec 15;135(47). pii: 46867. doi: 10.1002/app.46867. Epub 2018 Aug 27.


Cyclohexanone curcumin analogs inhibit the progression of castration-resistant prostate cancer in vitro and in vivo.

Mapoung S, Suzuki S, Fuji S, Naiki-Ito A, Kato H, Yodkeeree S, Ovatlarnporn C, Takahashi S, Limtrakul Dejkriengkraikul P.

Cancer Sci. 2019 Feb;110(2):596-607. doi: 10.1111/cas.13897. Epub 2018 Dec 21.


Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy.

Saadipoor A, Razzaghdoust A, Simforoosh N, Mahdavi A, Bakhshandeh M, Moghadam M, Abdollahi H, Mofid B.

Phytother Res. 2019 Feb;33(2):370-378. doi: 10.1002/ptr.6230. Epub 2018 Nov 14.


3D-QSAR and Molecular Docking Studies on Design Anti-prostate Cancer Curcumin Analogues.

Meng X, Cui L, Song F, Luan M, Ji J, Si H, Duan Y, Zhai H.

Curr Comput Aided Drug Des. 2018 Oct 29. doi: 10.2174/1573409914666181029123746. [Epub ahead of print]


Supplemental Content

Loading ...
Support Center